Recombinant Human Osteoprotegerin/TNFRSF11B Protein (His Tag) (Active)

Cat. No : CDRP-00417

size:

Target Information
Target Name	Osteoprotegerin/TNFRSF11B
Synonyms	Tumor necrosis factor receptor superfamily member 11B; Osteoclastogenesis inhibitory factor; Osteoprotegerin; TNFRSF11B; OCIF; OPG; PDB5; TR1
UniProt ID	P11413
Accession	O00300

Product Details
Expression Host	HEK293 Cells
Species	Human
Tag	C-His
Molar Mass	44.65 kDa
Sequence	Ala 49-Ser 745

Background
TNFRSF11B is a secreted protein; containing 2 death domains and 4 TNFR-Cys repeats. TNFRSF11B is a decoy receptor for the receptor activator of nuclear factor kappa B ligand (RANKL). By binding RANKL; TNFRSF11B inhibits nuclear kappa B (NF-κB) which is a central and rapid acting transcription factor for immune-related genes; and a key regulator of inflammation; innate immunity; and cell survival and differentiation. TNFRSF11B levels are influenced by voltage-dependent calcium channelsCav1. 2. TNFRSF11B can reduce the production of osteoclasts by inhibiting the differentiation of osteoclast precursors (osteoclasts are related to monocytes/macrophages and are derived from granulocyte/macrophage-forming colony units (CFU-GM)) into osteoclasts and also regulates the resorption of osteoclasts in vitroand in vivo. TNFRSF11B binding to RANKL on osteoblast/stromal cells; blocks the RANKL-RANK ligand interaction between osteoblast/stromal cells and osteoclast precursors. This has the effect of inhibiting the differentiation of the osteoclast precursor into a mature osteoclast.

Background

TNFRSF11B is a secreted protein; containing 2 death domains and 4 TNFR-Cys repeats. TNFRSF11B is a decoy receptor for the receptor activator of nuclear factor kappa B ligand (RANKL). By binding RANKL; TNFRSF11B inhibits nuclear kappa B (NF-κB) which is a central and rapid acting transcription factor for immune-related genes; and a key regulator of inflammation; innate immunity; and cell survival and differentiation. TNFRSF11B levels are influenced by voltage-dependent calcium channelsCav1. 2. TNFRSF11B can reduce the production of osteoclasts by inhibiting the differentiation of osteoclast precursors (osteoclasts are related to monocytes/macrophages and are derived from granulocyte/macrophage-forming colony units (CFU-GM)) into osteoclasts and also regulates the resorption of osteoclasts in vitroand in vivo. TNFRSF11B binding to RANKL on osteoblast/stromal cells; blocks the RANKL-RANK ligand interaction between osteoblast/stromal cells and osteoclast precursors. This has the effect of inhibiting the differentiation of the osteoclast precursor into a mature osteoclast.

Properties
Purity	>85% as determined by reducing SDS-PAGE.
Formulation	Lyophilized from a 0.2 μm filtered solution of 20 mM PBS, 150 mM NaCl, pH7.4.
Reconstitution	Please refer to the printed manual for detailed information.
Shipping	This product is provided as lyophilized powder which is shipped with ice packs.
Storage	Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80 °C. Reconstituted protein solution can be stored at 4-8 °C for 2-7 days. Aliquots of reconstituted samples are stable at < -20 °C for 3 months.

! For research use only. Not intended for any clinical use.